Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
PPH4
MCID: PLM121
MIFTS: 28

Pulmonary Hypertension, Primary, 4 (PPH4)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Pulmonary Hypertension, Primary, 4

About this section

MalaCards integrated aliases for Pulmonary Hypertension, Primary, 4:

Name: Pulmonary Hypertension, Primary, 4 58 76 74
Primary Pulmonary Hypertension 4 30 6
Pph4 58 76
Hypertension, Pulmonary, Primary, Type 4 41

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant

Miscellaneous:
progressive disorder
incomplete penetrance
variable age at onset (childhood to adulthood)


HPO:

33
pulmonary hypertension, primary, 4:
Onset and clinical course incomplete penetrance progressive
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Respiratory diseases Cardiovascular diseases Blood diseases
See all MalaCards categories (disease lists)


Sources

Summaries for Pulmonary Hypertension, Primary, 4

About this section
OMIM : 58 Primary pulmonary hypertension is a rare progressive disease characterized by increased pulmonary artery pressure in the absence of common causes of pulmonary hypertension, such as chronic heart, lung, or thromboembolic disease. There is often vascular remodeling. The clinical presentation can be nonspecific, and patients often receive a diagnosis late in their clinical course (summary by Ma et al., 2013). For a general phenotypic description and a discussion of genetic heterogeneity of primary pulmonary hypertension, see PPH1 (178600). (615344)

MalaCards based summary : Pulmonary Hypertension, Primary, 4, is also known as primary pulmonary hypertension 4. An important gene associated with Pulmonary Hypertension, Primary, 4 is KCNK3 (Potassium Two Pore Domain Channel Subfamily K Member 3). The drugs Spironolactone and Natriuretic Peptide, Brain have been mentioned in the context of this disorder. Affiliated tissues include endothelial and brain, and related phenotypes are arrhythmia and pulmonary arterial hypertension

UniProtKB/Swiss-Prot : 76 Pulmonary hypertension, primary, 4: A rare disorder characterized by plexiform lesions of proliferating endothelial cells in pulmonary arterioles. The lesions lead to elevated pulmonary arterial pression, right ventricular failure, and death. The disease can occur from infancy throughout life and it has a mean age at onset of 36 years. Penetrance is reduced. Although familial pulmonary hypertension is rare, cases secondary to known etiologies are more common and include those associated with the appetite-suppressant drugs.

Sources

Related Diseases for Pulmonary Hypertension, Primary, 4

About this section

Diseases in the Pulmonary Hypertension family:

Pulmonary Hypertension, Primary, 1 Pulmonary Hypertension, Primary, Autosomal Recessive
Pulmonary Hypertension, Primary, 2 Pulmonary Hypertension, Primary, 3
Pulmonary Hypertension, Primary, 4

Sources

Symptoms & Phenotypes for Pulmonary Hypertension, Primary, 4

About this section

Human phenotypes related to Pulmonary Hypertension, Primary, 4:

33
# Description HPO Frequency HPO Source Accession
1 arrhythmia 33 occasional (7.5%) HP:0011675
2 pulmonary arterial hypertension 33 HP:0002092
3 increased pulmonary vascular resistance 33 HP:0005317

Symptoms via clinical synopsis from OMIM:

58
Cardiovascular Vascular:
increased pulmonary vascular resistance
plexiform vascular lesions
increased pulmonary artery pressure
pulmonary arteries show medial hypertrophy
pulmonary arterial vascular wall remodeling
more
Cardiovascular Heart:
cardiac arrhythmias (in some patients)

Clinical features from OMIM:

615344
Sources

Drugs & Therapeutics for Pulmonary Hypertension, Primary, 4

About this section

Drugs for Pulmonary Hypertension, Primary, 4 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 17)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
2 Natriuretic Peptide, Brain Phase 4
3 Natriuretic Agents Phase 4
4 Diuretics, Potassium Sparing Phase 4
5 Mineralocorticoid Receptor Antagonists Phase 4
6 diuretics Phase 4
7 Mineralocorticoids Phase 4
8 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
9 Hormone Antagonists Phase 4
10 Hormones Phase 4
11
Ergonovine Approved Phase 3 60-79-7 443884
12
Oxytocin Approved, Vet_approved Phase 3 50-56-6 53477758 439302
13
Lactitol Investigational Phase 3 585-88-6, 585-86-4 493591
14 Oxytocics Phase 3
15 Gastrointestinal Agents Phase 3
16 Laxatives Phase 3
17 Cathartics Phase 3

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Spironolactone Therapy in Chronic Stable Right HF Trial Recruiting NCT03344159 Phase 4 Spironolactone;Placebo
2 Ergometrine Versus Oxytocin in the Management of Atonic Post-partum Haemorrhage (PPH) in Women Delivered Vaginally Unknown status NCT02306733 Phase 3 Ergometrine;Oxytocin

Search NIH Clinical Center for Pulmonary Hypertension, Primary, 4

Sources

Genetic Tests for Pulmonary Hypertension, Primary, 4

About this section

Genetic tests related to Pulmonary Hypertension, Primary, 4:

# Genetic test Affiliating Genes
1 Primary Pulmonary Hypertension 4 30 KCNK3
Sources

Anatomical Context for Pulmonary Hypertension, Primary, 4

About this section

MalaCards organs/tissues related to Pulmonary Hypertension, Primary, 4:

42
Endothelial, Brain
Sources

Publications for Pulmonary Hypertension, Primary, 4

About this section

Articles related to Pulmonary Hypertension, Primary, 4:

(show all 22)
# Title Authors Year
1
The niobium oxoazides [NbO(N3)3], [NbO(N3)3·2CH3CN], [(bipy)NbO(N3)3], Cs2[NbO(N3)5] and [PPh4]2[NbO(N3)5]. ( 27198621 )
2016
2
The Binary Group 4 Azides [PPh4 ]2 [Zr(N3 )6 ] and [PPh4 ]2 [Hf(N3 )6 ]. ( 27735115 )
2016
3
A novel channelopathy in pulmonary arterial hypertension. ( 23883380 )
2013
4
Unprecedented conformational variability in main group inorganic chemistry: the tetraazidoarsenite and -antimonite salts A+ [M(N3)4]- (A = NMe4, PPh4, (Ph3P)2N; M = As, Sb), five similar salts, five different anion structures. ( 23214472 )
2013
5
Syntheses and crystal structures of the closo-borate M[B8H9] (M = [PPh4]+ and [N(n-Bu4)]+). ( 22136316 )
2012
6
Syntheses and crystal structures of the closo-borates M2[B7H7] and M[B7H8] (M = PPh4, PNP, and N(n-Bu4)): the missing crystal structure in the series [B(n)H(n)]2- (n = 6-12). ( 21341737 )
2011
7
Dangling thiyl radical: stabilized in [PPh4]2[(bdt)W(VI)(O)(μ-S)2Cu(I)(SC6H4S•)]. ( 21452808 )
2011
8
Organic-soluble optically pure anionic metal complexes PPh4[M(III)(S,S-EDDS)].2H2O (M = Fe, Co, Cr). ( 20200720 )
2010
9
Structural chemistry of (PPh4)2M(WS4)2 materials. ( 18335143 )
2008
10
Copper halide-bridged ruthenium telluride carbonyl complexes: discovery of the semiconducting cluster chain polymer {[PPh4]2[Te2Ru4(CO)10Cu4Br2Cl2].THF}infinity. ( 17508380 )
2007
11
Molecular structure and theoretical studies of (PPh4)2[Bi10Cu10(SPh)24]. ( 17886824 )
2007
12
Construction of [(eta5-C5Me5)WS3Cu3]-based supramolecular compounds from preformed incomplete cubane-like clusters [PPh4][(eta5-C5Me5)WS3(CuX)3] (X = CN, Br). ( 16676966 )
2006
13
[PPh4]3[W(CN)7(O2)].4H2O as the representative of the [M(L)7(LL)] class for nine-coordinate complexes. ( 16933909 )
2006
14
Balancing framework densification with charged, halogen-bonded-pi-conjugated linkages: [PPh4]2{[E-TTF-I2][Re6Se8(CN)6]} versus [PPh4]2[EDT-TTF-I]2{[EDT-TTF-I][Re6Se8(CN)6]}. ( 17007403 )
2006
15
Acetic acid induced self-assembly of supramolecular compounds [Et4N]3[(WS4Cu2)2(mu-CN)3].2MeCN and [PPh4][WS4Cu3(mu-CN)2].MeCN from preformed clusters [A]2[WS4(CuCN)2] (A = Et4N, PPh4). ( 15877450 )
2005
16
Synthetic applications of (Me3SiNSN)2E (E = S, Se) in chalcogen-nitrogen chemistry: formation and structural characterization of Cl2TeESN2 (E = S, Se) and [PPh4]2[Pd2(mu-Se2N2S)X4] (X = Cl, Br). ( 15998027 )
2005
17
Single-molecule magnets: two-electron reduced version of a Mn12 complex and environmental influences on the magnetization relaxation of (PPh4)(2)[Mn(12)O(12)(O(2)CCHCl2)(16)(H2O)4]. ( 12643720 )
2003
18
Assembly of a supramolecular cube, [(Cp*WS3Cu3)8 Cl8(CN)12Li4] from a preformed incomplete cubane-like compound [PPh4][Cp*WS3(CuCN)3]. ( 14558796 )
2003
19
Preparation and crystal structure of tetraphenylphosphonium triiodotetrabromide [PPh4][I3Br4]. ( 11195382 )
2001
20
[Fe(Phen)(CN)4]-: a versatile building block for the design of heterometallic systems. Crystal structures and magnetic properties of PPh4[Fe(Phen)(CN)4]*2H2O and [[Fe(Phen)(CN)4]2M(H2O)2]*4H2O [Phen = 1,10-phenanthroline; M = Mn(II) and Zn(II)]. ( 11304151 )
2001
21
Complex Fluids Based on the Flexible One-Dimensional Mineral Polymers [K(MPS4 )]∞ (M=Ni, Pd): Autofragmentation to Concave, Cyclic (PPh4 )3 [(NiPS4 )3 ]. ( 29711512 )
1998
22
Ligand field transitions and the origin of zero field splitting in [PPh4][FeCl4] and [NEt4][Fe(SR)4] (R = 2,3,5,6-Me4C6H): a model for the high-spin Fe(III) site in rubredoxin. ( 22148807 )
1988
Sources

Variations for Pulmonary Hypertension, Primary, 4

About this section

UniProtKB/Swiss-Prot genetic disease variations for Pulmonary Hypertension, Primary, 4:

76
# Symbol AA change Variation ID SNP ID
1 KCNK3 p.Thr8Lys VAR_070126 rs108530743
2 KCNK3 p.Gly97Arg VAR_070127 rs398123040
3 KCNK3 p.Glu182Lys VAR_070128 rs398123042
4 KCNK3 p.Tyr192Cys VAR_070129 rs398123043
5 KCNK3 p.Gly203Asp VAR_070130 rs398123039
6 KCNK3 p.Val221Leu VAR_070131 rs398123041

ClinVar genetic disease variations for Pulmonary Hypertension, Primary, 4:

6 (show all 46)
# Gene Variation Type Significance SNP ID Assembly Location
1 KCNK3 NM_002246.2(KCNK3): c.608G> A (p.Gly203Asp) single nucleotide variant Pathogenic rs398123039 GRCh37 Chromosome 2, 26950859: 26950859
2 KCNK3 NM_002246.2(KCNK3): c.608G> A (p.Gly203Asp) single nucleotide variant Pathogenic rs398123039 GRCh38 Chromosome 2, 26727991: 26727991
3 KCNK3 NM_002246.2(KCNK3): c.289G> A (p.Gly97Arg) single nucleotide variant Pathogenic rs398123040 GRCh37 Chromosome 2, 26950540: 26950540
4 KCNK3 NM_002246.2(KCNK3): c.289G> A (p.Gly97Arg) single nucleotide variant Pathogenic rs398123040 GRCh38 Chromosome 2, 26727672: 26727672
5 KCNK3 NM_002246.2(KCNK3): c.661G> C (p.Val221Leu) single nucleotide variant Pathogenic rs398123041 GRCh37 Chromosome 2, 26950912: 26950912
6 KCNK3 NM_002246.2(KCNK3): c.661G> C (p.Val221Leu) single nucleotide variant Pathogenic rs398123041 GRCh38 Chromosome 2, 26728044: 26728044
7 KCNK3 NM_002246.2(KCNK3): c.544G> A (p.Glu182Lys) single nucleotide variant Pathogenic rs398123042 GRCh37 Chromosome 2, 26950795: 26950795
8 KCNK3 NM_002246.2(KCNK3): c.544G> A (p.Glu182Lys) single nucleotide variant Pathogenic rs398123042 GRCh38 Chromosome 2, 26727927: 26727927
9 KCNK3 NM_002246.2(KCNK3): c.575A> G (p.Tyr192Cys) single nucleotide variant Pathogenic rs398123043 GRCh37 Chromosome 2, 26950826: 26950826
10 KCNK3 NM_002246.2(KCNK3): c.575A> G (p.Tyr192Cys) single nucleotide variant Pathogenic rs398123043 GRCh38 Chromosome 2, 26727958: 26727958
11 KCNK3 NM_002246.2(KCNK3): c.23C> A (p.Thr8Lys) single nucleotide variant Pathogenic rs1085307438 GRCh37 Chromosome 2, 26915766: 26915766
12 KCNK3 NM_002246.2(KCNK3): c.23C> A (p.Thr8Lys) single nucleotide variant Pathogenic rs1085307438 GRCh38 Chromosome 2, 26692898: 26692898
13 KCNK3 NM_002246.2(KCNK3): c.17T> C (p.Val6Ala) single nucleotide variant Uncertain significance rs1226314697 GRCh38 Chromosome 2, 26692892: 26692892
14 KCNK3 NM_002246.2(KCNK3): c.17T> C (p.Val6Ala) single nucleotide variant Uncertain significance rs1226314697 GRCh37 Chromosome 2, 26915760: 26915760
15 KCNK3 NM_002246.2(KCNK3): c.172G> A (p.Gly58Ser) single nucleotide variant Uncertain significance rs753384871 GRCh37 Chromosome 2, 26915915: 26915915
16 KCNK3 NM_002246.2(KCNK3): c.172G> A (p.Gly58Ser) single nucleotide variant Uncertain significance rs753384871 GRCh38 Chromosome 2, 26693047: 26693047
17 KCNK3 NM_002246.2(KCNK3): c.654G> T (p.Pro218=) single nucleotide variant Benign rs34292597 GRCh37 Chromosome 2, 26950905: 26950905
18 KCNK3 NM_002246.2(KCNK3): c.654G> T (p.Pro218=) single nucleotide variant Benign rs34292597 GRCh38 Chromosome 2, 26728037: 26728037
19 KCNK3 NM_002246.2(KCNK3): c.366C> T (p.Leu122=) single nucleotide variant Likely benign rs61736657 GRCh37 Chromosome 2, 26950617: 26950617
20 KCNK3 NM_002246.2(KCNK3): c.366C> T (p.Leu122=) single nucleotide variant Likely benign rs61736657 GRCh38 Chromosome 2, 26727749: 26727749
21 KCNK3 NM_002246.2(KCNK3): c.423C> A (p.His141Gln) single nucleotide variant Likely benign rs151228365 GRCh37 Chromosome 2, 26950674: 26950674
22 KCNK3 NM_002246.2(KCNK3): c.423C> A (p.His141Gln) single nucleotide variant Likely benign rs151228365 GRCh38 Chromosome 2, 26727806: 26727806
23 KCNK3 NM_002246.2(KCNK3): c.1180G> A (p.Val394Met) single nucleotide variant Uncertain significance rs1553387738 GRCh37 Chromosome 2, 26951431: 26951431
24 KCNK3 NM_002246.2(KCNK3): c.1180G> A (p.Val394Met) single nucleotide variant Uncertain significance rs1553387738 GRCh38 Chromosome 2, 26728563: 26728563
25 KCNK3 NM_002246.2(KCNK3): c.100G> A (p.Glu34Lys) single nucleotide variant Uncertain significance rs1553383771 GRCh37 Chromosome 2, 26915843: 26915843
26 KCNK3 NM_002246.2(KCNK3): c.100G> A (p.Glu34Lys) single nucleotide variant Uncertain significance rs1553383771 GRCh38 Chromosome 2, 26692975: 26692975
27 KCNK3 NM_002246.2(KCNK3): c.832A> T (p.Ser278Cys) single nucleotide variant Uncertain significance rs368524386 GRCh37 Chromosome 2, 26951083: 26951083
28 KCNK3 NM_002246.2(KCNK3): c.832A> T (p.Ser278Cys) single nucleotide variant Uncertain significance rs368524386 GRCh38 Chromosome 2, 26728215: 26728215
29 KCNK3 NM_002246.2(KCNK3): c.1014G> A (p.Thr338=) single nucleotide variant Likely benign rs375930383 GRCh37 Chromosome 2, 26951265: 26951265
30 KCNK3 NM_002246.2(KCNK3): c.1014G> A (p.Thr338=) single nucleotide variant Likely benign rs375930383 GRCh38 Chromosome 2, 26728397: 26728397
31 KCNK3 NM_002246.2(KCNK3): c.365T> C (p.Leu122Pro) single nucleotide variant Likely pathogenic rs1553387422 GRCh38 Chromosome 2, 26727748: 26727748
32 KCNK3 NM_002246.2(KCNK3): c.365T> C (p.Leu122Pro) single nucleotide variant Likely pathogenic rs1553387422 GRCh37 Chromosome 2, 26950616: 26950616
33 KCNK3 NM_002246.2(KCNK3): c.834C> A (p.Ser278Arg) single nucleotide variant Uncertain significance GRCh38 Chromosome 2, 26728217: 26728217
34 KCNK3 NM_002246.2(KCNK3): c.834C> A (p.Ser278Arg) single nucleotide variant Uncertain significance GRCh37 Chromosome 2, 26951085: 26951085
35 KCNK3 NM_002246.2(KCNK3): c.953G> A (p.Arg318His) single nucleotide variant Uncertain significance GRCh38 Chromosome 2, 26728336: 26728336
36 KCNK3 NM_002246.2(KCNK3): c.953G> A (p.Arg318His) single nucleotide variant Uncertain significance GRCh37 Chromosome 2, 26951204: 26951204
37 KCNK3 NM_002246.2(KCNK3): c.547C> T (p.His183Tyr) single nucleotide variant Uncertain significance GRCh38 Chromosome 2, 26727930: 26727930
38 KCNK3 NM_002246.2(KCNK3): c.547C> T (p.His183Tyr) single nucleotide variant Uncertain significance GRCh37 Chromosome 2, 26950798: 26950798
39 KCNK3 NM_002246.2(KCNK3): c.646_651dup (p.Gln217_Pro218insThrGln) duplication Uncertain significance GRCh38 Chromosome 2, 26728029: 26728034
40 KCNK3 NM_002246.2(KCNK3): c.646_651dup (p.Gln217_Pro218insThrGln) duplication Uncertain significance GRCh37 Chromosome 2, 26950897: 26950902
41 KCNK3 NM_002246.2(KCNK3): c.844A> G (p.Thr282Ala) single nucleotide variant Uncertain significance GRCh38 Chromosome 2, 26728227: 26728227
42 KCNK3 NM_002246.2(KCNK3): c.844A> G (p.Thr282Ala) single nucleotide variant Uncertain significance GRCh37 Chromosome 2, 26951095: 26951095
43 KCNK3 NM_002246.2(KCNK3): c.1169G> A (p.Arg390His) single nucleotide variant Uncertain significance GRCh38 Chromosome 2, 26728552: 26728552
44 KCNK3 NM_002246.2(KCNK3): c.1169G> A (p.Arg390His) single nucleotide variant Uncertain significance GRCh37 Chromosome 2, 26951420: 26951420
45 KCNK3 NM_002246.3(KCNK3): c.250_267dup (p.Thr89_Val90insPheTyrPheAlaIleThr) duplication Uncertain significance GRCh38 Chromosome 2, 26693125: 26693142
46 KCNK3 NM_002246.3(KCNK3): c.250_267dup (p.Thr89_Val90insPheTyrPheAlaIleThr) duplication Uncertain significance GRCh37 Chromosome 2, 26915993: 26916010
Sources

Expression for Pulmonary Hypertension, Primary, 4

About this section
Search GEO for disease gene expression data for Pulmonary Hypertension, Primary, 4.
Sources

Pathways for Pulmonary Hypertension, Primary, 4

About this section
Sources

GO Terms for Pulmonary Hypertension, Primary, 4

About this section
Sources

Sources for Pulmonary Hypertension, Primary, 4

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....